| Hazard Information | Back Directory | [Uses]
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1]. | [in vivo]
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2]. | Animal Model: | MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] | | Dosage: | 5 mg/kg | | Administration: | IP, twice a week, 3weeks | | Result: | Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group. |
| [References]
[1] Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542. DOI:10.3389/fimmu.2022.924542
[2] Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|